{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:40:35Z","timestamp":1792856435604,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jacl.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:22:52Z","timestamp":1753226572000},"page":"1468-1475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8804-2014","authenticated-orcid":false,"given":"Ryohei","family":"Tanigawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-2889","authenticated-orcid":false,"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-4185","authenticated-orcid":false,"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.jacl.2025.07.006_bib0001","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jacl.2025.07.006_bib0002","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamacardio.2022.0912","article-title":"Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations","volume":"7","author":"Liu","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2025.07.006_bib0003","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1210\/clinem\/dgad406","article-title":"Does elevated high-density lipoprotein cholesterol protect against cardiovascular disease?","volume":"109","author":"Razavi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.07.006_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9150(85)90064-4","article-title":"Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia","volume":"58","author":"Koizumi","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.07.006_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0021-9150(88)90094-9","article-title":"Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity","volume":"70","author":"Yamashita","year":"1988","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2025.07.006_bib0006","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00041433-199510000-00010","article-title":"Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis","volume":"6","author":"Bruce","year":"1995","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2025.07.006_bib0007","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5551\/jat.11.110","article-title":"Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese","volume":"11","author":"Nagano","year":"2004","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.jacl.2025.07.006_bib0008","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(02)00327-1","article-title":"Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia","volume":"166","author":"Maruyama","year":"2003","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2025.07.006_bib0009","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.ATV.15.11.1849","article-title":"Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase","volume":"15","author":"Hirano","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"18","key":"10.1016\/j.jacl.2025.07.006_bib0010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.07.006_bib0011","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1006\/pmed.1998.0340","article-title":"A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency","volume":"27","author":"Moriyama","year":"1998","journal-title":"Prev Med"},{"issue":"2","key":"10.1016\/j.jacl.2025.07.006_bib0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.jbchem.a124516","article-title":"Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins","volume":"116","author":"Ishigami","year":"1994","journal-title":"J Biochem"},{"issue":"2","key":"10.1016\/j.jacl.2025.07.006_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(00)00574-8","article-title":"Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia","volume":"152","author":"Yamashita","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.07.006_bib0014","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARMa), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2025.07.006_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial","volume":"25","author":"Arai","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.jacl.2025.07.006_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor a modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2025.07.006_bib0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5551\/jat.64112","article-title":"Efficacy and safety of Pemafibrate, a novel selective ppar\u03b1 modulator in Chinese patients with dyslipidemia: A double-masked, randomized, Placebo- and active-controlled comparison trial","volume":"32","author":"Dai","year":"2025","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"10.1016\/j.jacl.2025.07.006_bib0018","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of Pemafibrate, a novel selective ppar\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jacl.2025.07.006_bib0019","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/dom.13686","article-title":"Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study","volume":"21","author":"Araki","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.jacl.2025.07.006_bib0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-2275(20)30123-1","article-title":"A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC","volume":"43","author":"Usui","year":"2002","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.jacl.2025.07.006_bib0021","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/01.ATV.0000155017.60171.88","article-title":"Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography","volume":"25","author":"Okazaki","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.jacl.2025.07.006_bib0022","doi-asserted-by":"crossref","first-page":"974","DOI":"10.5551\/jat.60764","article-title":"Distinct differences in lipoprotein particle number evaluation between GP-HPLC and NMR: analysis in dyslipidemic patients administered a selective ppar\u03b1 modulator, pemafibrate","volume":"28","author":"Yamashita","year":"2021","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.jacl.2025.07.006_bib0023","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacl.2019.01.002","article-title":"Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency","volume":"13","author":"Okada","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2025.07.006_bib0024","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","article-title":"Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia","volume":"12","author":"Yamashita","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.jacl.2025.07.006_bib0025","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.116.305485","article-title":"HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export","volume":"116","author":"Du Xian-M","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2025.07.006_bib0026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ebiom.2017.03.018","article-title":"ATP-binding cassette transporter A1 deficiency in human induced pluripotent stem cell-derived hepatocytes abrogates HDL biogenesis and enhances triglyceride secretion","volume":"18","author":"Bi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jacl.2025.07.006_bib0027","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","article-title":"HDL and reverse cholesterol transport","volume":"124","author":"Ouimet","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2025.07.006_bib0028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2025.07.006_bib0029","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tem.2017.02.001","article-title":"SR-BI: a multifunctional receptor in cholesterol homeostasis and atherosclerosis","volume":"28","author":"Linton MacRae","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.jacl.2025.07.006_bib0030","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1074\/jbc.M211627200","article-title":"Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice","volume":"278","author":"Mardones","year":"2003","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.jacl.2025.07.006_bib0031","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.bbalip.2017.05.005","article-title":"Ectopic adenine nucleotide translocase activity controls extracellular ADP levels and regulates the F1-ATPase-mediated HDL endocytosis pathway on hepatocytes","volume":"1862","author":"Cardouat","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.jacl.2025.07.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/356432","article-title":"ATP synthase \u03b2-chain overexpression in SR-BI knockout mice increases HDL uptake and reduces plasma HDL level","volume":"2014","author":"Song","year":"2014","journal-title":"Int J Endocrinol"},{"issue":"11","key":"10.1016\/j.jacl.2025.07.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166215","article-title":"Regulation of the expression of cholesterol transporters by lipid-lowering drugs ezetimibe and pemafibrate in rat liver and intestine","volume":"1867","author":"Tanaka","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"15","key":"10.1016\/j.jacl.2025.07.006_bib0034","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1177\/2047487319894114","article-title":"Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease","volume":"27","author":"Feng","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.07.006_bib0035","article-title":"Effects of pemafibrate on LDL-C and related lipid markers in patients with MASLD: a sub-analysis of the PEMA-FL study","author":"Tanigawa","year":"2024","journal-title":"J Atheroscler Thromb"},{"issue":"21","key":"10.1016\/j.jacl.2025.07.006_bib0036","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacl.2025.07.006_bib0037","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacl.2025.07.006_bib0038","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2025.07.006_bib0039","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors","volume":"122","author":"Tall Alan","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2025.07.006_bib0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.atherosclerosis.2018.09.035","article-title":"Cholesteryl ester transfer protein: an enigmatic pharmacology - antagonists and agonists","volume":"278","author":"Yamashita","year":"2018","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:50:04Z","timestamp":1772895004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1933287425003460"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.07.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}